Humana Denial Appeal - Free AI Letter Generator | Counterclaim

Common Humana denial patterns

These are the denial patterns we see most often from Humana members based on publicly-reported insurer policies and regulator findings. The right appeal approach depends on which pattern matches your denial.

• Medicare Advantage prior-authorization denials for skilled nursing facility stays, home health, and DME
• Medical-necessity denials for advanced imaging, oncology drugs, and orthopedic procedures
• Step-therapy denials on Part B and Part D drugs
• Out-of-network denials on HMO plans where the patient could have used an in-network alternative
• Coverage determinations for outpatient observation versus inpatient admission
• Part D formulary exclusions and tier-placement denials
• Post-acute-care denials for SNF, inpatient rehab, and long-term acute care

How Humana's appeal process works

Humana commercial appeals follow ERISA / state-law timelines (generally 180 days). Humana Medicare Advantage appeals follow CMS rules: a 60-day window for standard reconsideration, 72-hour decision for expedited, automatic escalation to a CMS-contracted Independent Review Entity (MAXIMUS Federal Services) if denied at the plan level. Humana's denial letter will state which appeal path applies.

Step 1: Identify the product. The denial notice will say Medicare Advantage, Medicare Part D, commercial, Medicaid, or TRICARE - the appeal path differs for each. Step 2: For Medicare Advantage, file a written 'reconsideration' within 60 days of the denial. Use the address or fax on the denial notice. Include the member ID, the authorization or claim number, the relevant clinical evidence, and a physician letter of medical necessity. Step 3: Mark the reconsideration expedited if standard timing would jeopardize health - decision must come within 72 hours, and physicians can request expedited on the member's behalf. Step 4: If Humana upholds the denial at reconsideration, the case is automatically forwarded to MAXIMUS Federal Services as the IRE - the patient does not need to file separately. Step 5: If MAXIMUS upholds the denial, the patient can request an Administrative Law Judge hearing through OMHA when the amount in controversy meets the threshold (annually adjusted). Step 6: For Part D drug denials, file a coverage determination request with the plan first, then redetermination if denied, then auto-forward to the IRE. Step 7: For commercial / ASO Humana plans, follow ERISA timelines - 180 days to file, 30 to 60-day decision standard, 72 hours expedited, external review through state IRO or plan-selected IRO.

What makes Humana appeals succeed

Humana Medicare Advantage appeals succeed most often when they: (1) cite the relevant Medicare benefit policy manual section (CMS Pub. 100-02) and demonstrate that the requested service meets traditional Medicare coverage rules - the OIG has repeatedly flagged that MA plans deny services that traditional Medicare would cover, and the 2024 CMS final rules now expressly require MA plans to honor traditional Medicare coverage criteria; (2) invoke the prudent-layperson standard for emergency-room denials and attach the ER record establishing presenting symptoms; (3) for Skilled Nursing Facility, home-health, and post-acute denials, attach the SNF medical record and reference the Jimmo v. Sebelius settlement clarifying that improvement is not required for skilled-care coverage; (4) request expedited review when discharge or service interruption is imminent, with physician confirmation of clinical urgency; (5) for SNF discharge specifically, invoke the BFCC-QIO immediate-review right by calling the QIO number on the Notice of Medicare Non-Coverage by midnight of the day before discharge - the SNF cannot discharge until the QIO decides; (6) preserve the auto-forwarding right at level 2 by being aware that the case automatically goes to MAXIMUS without a separate filing; and (7) for Part D drug denials, use the formulary exception or tiering exception process with documented prior-failed-therapy or contraindication evidence, which is the controlling pathway for non-formulary drug coverage.

Recent regulatory and public-record context

Humana was named in the October 2024 Senate Permanent Subcommittee on Investigations report on Medicare Advantage post-acute-care prior-authorization denials by major MA carriers. The HHS OIG's 2022 audit of MA prior-authorization denials by major plans (including Humana) found that 13 percent of denials met traditional Medicare coverage rules. CMS issued final rules in 2023 and 2024 tightening MA prior-authorization standards, requiring plans to honor coverage criteria no more restrictive than traditional Medicare and to apply additional process protections - these rules give MA member appeals additional regulatory grounding.

Frequently asked questions: Humana appeals

Related guides for Humana members